Professor Nagy Habib is an academic surgeon and in July 2003 was awarded the position of professor of hepatobiliary surgery in the department of surgery and cancer, Faculty of Medicine, Imperial College London. He is director of the hepatopancreatobiliary (HPB) unit at Hammersmith Hospital, and in June 2007 was appointed a Pro Rector of Imperial College London and member of the College Management Board. Professor Nagy Habib pioneered the first clinical trial in the use of adenovirus for the treatment of liver cancer, as well as the use of plasmid gene therapy for hydrodynamic gene delivery. He is the first person in the West to publish a clinical trial on the use of autologous adult bone marrow-derived stem cells and RNA activation for the treatment of patients with liver insufficiency and liver cancer. He was selected as one of the top 10 surgeons in the UK by the Saturday Times Magazine and he was honoured to be elected to join the French Academy of Surgeons and the European Surgical Association. He held a gold award from the Advisory Committee for Clinical Excellencem, and the Winner of a Takreem Laureate award in 2012. He invented the Habib 4x liver resection device (acquired by AngioDynamics Inc 2015), and the Habib EndoHPB (won an Edison Gold award for Medical Innovation in 2020). He is the Founder of EMcision Ltd (medical device innovation), MiNA therapeutics (RNA therapeutics), Apterna (aptamer development), and Dawn Therapeutics (gene therapy). And he also elected Member of the French Académie Nationale de Chirurgie (2015). He has published more than 340 articles in scientific journals.